02 July 2018
What is real-world data (RWD) and real-world evidence (RWE)? Real-world data refers to health care data gathered from a variety of sources, outside of randomized controlled clinical trials. These data sources can include electronic medical records (EMRs), health insurance claims, genomic data, and data from health apps, wearables, and other biometric devices. Real-world evidence refers to the insights that are generated from these data.
The Food and Drug Administration (FDA) refers to RWE as “the clinical evidence regarding the usage and potential benefits or risks of a medical product derived from analysis of RWD.”1 For a detailed discussion about what RWE is, what it does, and how it helps biopharma companies develop products safely and effectively, refer to our inaugural RWE benchmark survey from 2017, Getting real with real-world evidence.
Since the publication of our first survey in Spring 2017, regulators have advanced RWE initiatives (see sidebar, “The advancing regulatory science of RWE”), and some companies have been aggressive in their strategy to access RWD and generate RWE. For instance, in February 2018, Roche announced the acquisition of Flatiron Health, a health care technology company with a large oncology-EMR system, for US$2 billion. Roche cited the possibility of harnessing the EMR data for research purposes— potentially speeding up and improving drug development—as a key driver of the decision.
For this year’s survey, we sought to understand more about what’s inspiring companies to take such bold steps to access and use RWD and what investments they are making in this area (for more detail on this year’s survey see the sidebar, “Survey methodology”). Our survey results reveal that:
• RWE is being used to achieve key strategic priorities across the product life cycle.
• Companies are investing in people, data, and technology (including machine learning) to build internal capabilities.
• Increasing use of nontraditional data sources will likely require external strategic partnerships.
• Internal and external barriers threaten the success of RWE initiatives.
How are life sciences companies using real-world evidence? Access the full findings of the Deloitte Center for Health Solutions 2018 RWE benchmarking survey.
The survey, which is based on interviews with RWE, IT, scientific, medical, and business executives from global life sciences companies, explores the perceived value, capabilities, and barriers to utilizing RWE.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Batyr Berdyklychev is now head of the WHO office in Russia
07 May 2024
Russia expects more medical tourism due to the world’s first drug for ankylosing spondylitis
07 May 2024
Health Ministry registered Russian drug for ankylosing spondylitis
06 May 2024
How gut enzymes could make universal donor blood possible
06 May 2024